GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rocket Pharmaceuticals Inc (NAS:RCKT) » Definitions » Cyclically Adjusted Book per Share

Rocket Pharmaceuticals (Rocket Pharmaceuticals) Cyclically Adjusted Book per Share : $8.04 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Rocket Pharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Rocket Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2024 was $4.871. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $8.04 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Rocket Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 52.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-05-31), Rocket Pharmaceuticals's current stock price is $21.30. Rocket Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $8.04. Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 2.65.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Rocket Pharmaceuticals was 4.88. The lowest was 0.00. And the median was 0.00.


Rocket Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for Rocket Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rocket Pharmaceuticals Cyclically Adjusted Book per Share Chart

Rocket Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 7.98

Rocket Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.29 6.50 6.54 7.98 8.04

Competitive Comparison of Rocket Pharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Rocket Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rocket Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4.871/131.7762*131.7762
=4.871

Current CPI (Mar. 2024) = 131.7762.

Rocket Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.000 100.560 0.000
201409 -0.093 100.428 -0.122
201412 -15.094 99.070 -20.077
201503 8.318 99.621 11.003
201506 7.771 100.684 10.171
201509 17.641 100.392 23.156
201512 16.472 99.792 21.751
201603 15.023 100.470 19.704
201606 14.176 101.688 18.370
201609 12.633 101.861 16.343
201612 10.845 101.863 14.030
201703 9.377 102.862 12.013
201706 8.520 103.349 10.864
201709 7.505 104.136 9.497
201712 7.018 104.011 8.891
201803 4.318 105.290 5.404
201806 3.976 106.317 4.928
201809 3.605 106.507 4.460
201812 4.293 105.998 5.337
201903 3.925 107.251 4.823
201906 4.937 108.070 6.020
201909 4.606 108.329 5.603
201912 5.611 108.420 6.820
202003 5.189 108.902 6.279
202006 4.831 108.767 5.853
202009 4.381 109.815 5.257
202012 8.255 109.897 9.898
202103 7.743 111.754 9.130
202106 7.714 114.631 8.868
202109 7.536 115.734 8.581
202112 7.049 117.630 7.897
202203 6.473 121.301 7.032
202206 5.889 125.017 6.207
202209 5.414 125.227 5.697
202212 6.189 125.222 6.513
202303 5.707 127.348 5.905
202306 5.005 128.729 5.123
202309 6.002 129.860 6.091
202312 5.456 129.419 5.555
202403 4.871 131.776 4.871

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Rocket Pharmaceuticals  (NAS:RCKT) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=21.30/8.04
=2.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Rocket Pharmaceuticals was 4.88. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Rocket Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Rocket Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Rocket Pharmaceuticals (Rocket Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
9 Cedarbrook Drive, Cranbury, NJ, USA, 08512
Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
Executives
John Militello officer: See Remarks C/O IMMUNE PHARMACEUTICALS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Gotham Makker director 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Gaurav Shah director, officer: See Remarks 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Kinnari Patel officer: Chief Operating Officer 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Mark Andrew White officer: Chief Medical Officer C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY NJ 08512
Jonathan David Schwartz officer: Chief Medical Officer 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Fady Ibraham Malik director 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Martin Wilson officer: General Counsel C/O TELIGENT, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
Carlos Garcia-parada officer: Chief Financial Officer C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE SUITE 7530, NEW YORK NY 10118
Elisabeth Bjork director C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10116
Kamran Alam officer: SVP - Finance & PFO 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118
David P Southwell director, officer: See Remarks C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421
Naveen Yalamanchi director 412 WEST 15TH STREET, 9TH FLOOR, NEW YORK NY 10019
Brian Batchelder officer: See Remarks 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016